NCT03836885 (APOLP) is a Phase 2 clinical trial of Apremilast in Oral Lichen Planus, sponsored by Sunnybrook Health Sciences Centre.

Who is sponsoring NCT03836885?

NCT03836885 is sponsored by Sunnybrook Health Sciences Centre.

What drugs are being tested in NCT03836885?

Interventions in NCT03836885: Apremilast, Placebo.

What condition does NCT03836885 study?

NCT03836885 studies Oral Lichen Planus.

Is NCT03836885 still recruiting?

NCT03836885 is currently withdrawn. Last updated 25 June 2020.

Last reviewed 2020-06-25 · How we verify

NCT03836885: APOLP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apremilast - Oral Lichen Planus Trial

Withdrawn Phase 2 Last updated 25 June 2020

What this trial tests

Phase 2 trial testing Apremilast in Oral Lichen Planus. Withdrawn.

Timeline

21 November 2019

Primary endpoint
22 April 2020

22 April 2020

Quick facts

Lead sponsor	Sunnybrook Health Sciences Centre
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Start date	21 November 2019
Primary completion	22 April 2020
Estimated completion	22 April 2020
Sites	1 location across Canada

Drugs / interventions tested

Apremilast (APREMILAST) — full drug profile →
Placebo

Conditions studied

Oral Lichen Planus — all drugs for Oral Lichen Planus →

Sponsor

Sunnybrook Health Sciences Centre — full company profile →

Who can join

18 and older, any sex, with Oral Lichen Planus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Apremilast for the management of oral lichen planus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Apremilast

Trials testing the same drug.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07432386 — Methotrexate Versus Apremilast for Pruritus in Psoriasis · Phase 4 · not yet recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT07337434 — To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Present · EARLY_PHASE1 · recruiting

Other recruiting trials for Oral Lichen Planus

Currently open trials in the same condition.

NCT06981767 — Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus · Phase 2 · recruiting
NCT07131813 — Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus · Phase 4 · recruiting
NCT06932848 — The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus · NA · recruiting
NCT07100613 — Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus · Phase 2 · recruiting
NCT06233591 — Evaluating LP-10 in Subjects With OLP · Phase 2 · active not recruiting

Other Sunnybrook Health Sciences Centre trials

Trials by the same sponsor.

NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03836885 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
Last refreshed: 25 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03836885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing